Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2005

View Archived Issues

Novel IKK-2 inhibitor shows promise for the treatment of rheumatoid arthritis

Phase I for Vernalis/Serono collaborative compound

Pfizer to acquire Angiosyn

MedImmune files IND for phase I study of RSV/PIV-3 candidate vaccine

Compound from Merck & Co./Karo Bio collaboration enters clinic

BCX-2798 prevents lethal synergism between paramyxovirus and S. pneumoniae in mice

Preclinical data indicate efficacy of the VEGF pathway-targeted siRNA, ICS-283

New phase III and II data for SPP-100 for hypertension

Macugen now available

Bolder BioTechnology awarded SBIR grant to develop arthritis treatment

European CHMP reviews COX-2 inhibitors

Zalypsis enters phase I

Schering-Plough to acquire NeoGenesis

Aclasta recommended for approval for Paget's disease in Europe

Cotara enters new glioblastoma multiforme study

IND acceptance allows initiation of phase I trials of oleoyl estrone

Thalidomide receives orphan drug status in Japan

Solvay completes acquisition of Neopharma

Phase III data on the safety and analgesic efficacy of M6G in postoperative pain

Good safety profile reported for CEA-TRICOM vaccines in advanced cancer patients

In vitro evidence for the antitumor effects of oleic acid in breast cancer

Update on the pharmacological effects and safety profile of GHRP-2

Agents for the treatment of Alzheimer's disease reported by Merck

Scientists at GlaxoSmithKline describe histamine H3 receptor antagonists

Bayer presents DGAT-1 inhibitors for obesity and related disorders

New agents for type 2 diabetes mellitus covered by Merck patent

Agents for HIV infection disclosed in a patent

New 5-HT2A receptor antagonists for CNS disorders designed at Merck

New compounds for treatment of obesity identified by Novo Nordisk team

Contribution of IL-7 to the elimination of HIV-1 reservoirs/News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...